Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 34Standard of Care 32Carboplatin 32Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Cisplatin 24Gemcitabine 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 18Docetaxel 18Rituximab 16Irinotecan 16Cetuximab 16Drug Therapy 15Doxorubicin 15dostarlimab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13Prednisone 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × E-7386 × 1 year × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03264664 2026-03-06

Study of E7386 in Participants With Selected Advanced Neoplasms

Eisai Inc.

Phase 1 Active not recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡